Comparative Pharmacology
Head-to-head clinical analysis: TZ 3 versus ZURNAI AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TZ 3 versus ZURNAI AUTOINJECTOR.
TZ-3 vs ZURNAI (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
(S)-3-(4-(2-((3-fluorophenyl)amino)-2-oxoethyl)piperazin-1-yl)-N,N-dimethylpropanamide; selectively inhibits the interaction between the PD-1/PD-L1 immune checkpoint, blocking the PD-1/PD-L1 pathway and restoring antitumor T-cell function.
Hyaluronidase degradation of interstitial hyaluronan, increasing tissue permeability to facilitate fluid dispersion and drug absorption.
100 mg orally twice daily
Epinephrine 0.3 mg intramuscularly (into anterolateral thigh) every 5-15 minutes as needed for anaphylaxis.
None Documented
None Documented
12–18 hours (terminal). Steady-state achieved in ~3 days. Extended to ~30 hours in severe renal impairment.
Terminal elimination half-life is approximately 2.5 hours in adults. In renal impairment, half-life may extend up to 6 hours, necessitating dosing adjustments.
Primarily renal (60–70% unchanged), with 20–30% biliary/fecal, and <10% metabolized. Dosage adjustment required in renal impairment.
Primarily renal excretion as unchanged drug or acetylated metabolite (about 70-80% of the dose). A small fraction undergoes biliary/fecal excretion (<10%).
Category C
Category C
Unknown
Unknown